Flurry Of Upcoming Events Could Trigger Santarus Shares Over Next 2-3 Months

This Morning Cowen & Co. reiterated their “Neutral” rating for Santarus, Inc. (NASDAQ: SNTS), while raising their estimates for the company.

The Firm said Santarus faces three key events over the next 2-3 months, at least two of which could significantly move the shares. The most important catalyst will be the district court ruling on the validity of the five listed patents covering Santarus’s Zegerid (GERD): we anticipate a Q1:10 decision. FDA review deadlines for Santarus’s Zegerid tablets and Merck/Santarus’s OTC Zegerid capsules are coming in early December (12/4 and 12/9, respectively): each approval could bolster the market acceptance and penetration of Zegerid.”

The Firm raised its EPS estimates for FY09 to $0.17 from ($0.05) earlier, FY10 EPS revised to $0.20 from $0.10.While for FY11 and FY12, estimated EPS are $0.25 and $0.30 respectively.